Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/10/2025

Diagnostic Approach and Management of Hemolysis

Initial Diagnostic Workup

  • The American Society of Clinical Oncology recommends a comprehensive laboratory workup for suspected hemolysis, including complete blood count with indices, reticulocyte count, peripheral blood smear, LDH, haptoglobin, bilirubin levels, and direct antiglobulin test (DAT) to establish the diagnosis and determine the underlying cause 1, 2
  • Assess for reticulocytosis, which indicates adequate bone marrow response to hemolysis; normal or low reticulocyte count with evidence of hemolysis suggests concurrent bone marrow suppression 1, 2
  • Examine peripheral blood smear for abnormal red cell morphology that may suggest specific causes of hemolysis, such as schistocytes in microangiopathic hemolytic anemia or spherocytes in hereditary spherocytosis 1, 2
  • Measure LDH, unconjugated bilirubin, and haptoglobin to confirm hemolysis 1, 2
  • Perform direct antiglobulin test (DAT) to differentiate immune from non-immune causes 1, 2

Additional Testing Based on Initial Results

  • If DAT is positive, perform antibody identification, cold agglutinin testing, or drug-induced antibody testing to determine the underlying cause of immune-mediated hemolysis 1, 2
  • Evaluate autoimmune serology and consider paroxysmal nocturnal hemoglobinuria (PNH) screening if DAT is positive 1, 2
  • If DAT is negative, evaluate for thrombotic microangiopathies with ADAMTS13 activity and inhibitor titer, and check for glucose-6-phosphate dehydrogenase deficiency if oxidative stress is suspected 1, 4
  • Consider hereditary causes such as membrane disorders or enzymopathies if DAT is negative 1, 2

Management Based on Severity and Cause

  • For Grade 1 Hemolysis, provide close clinical follow-up and laboratory evaluation, and consider folic acid supplementation (1 mg daily) 1, 2
  • For Grade 2 Hemolysis, consider prednisone 0.5-1 mg/kg/day if immune-mediated, and identify and discontinue causative medications 1, 2
  • For Grade 3 Hemolysis, provide hematology consultation, prednisone 1-2 mg/kg/day, and consider RBC transfusion per existing guidelines 1, 2
  • For Grade 4 Hemolysis, provide immediate hospital admission, urgent hematology consultation, and IV prednisone 1-2 mg/kg/day, and consider rituximab, IVIG, cyclosporin A, or mycophenolate mofetil for severe immune-mediated hemolysis 1, 2

Special Considerations

  • For hyperhemolysis in sickle cell disease, consider high-dose steroids and IVIG as first-line treatment, followed by eculizumab for patients who continue to deteriorate 6
  • In patients with suspected pyruvate kinase deficiency, specific enzyme activity measurement and genetic testing should be performed 7, 8
  • For hemolysis related to immune checkpoint inhibitor therapy, management includes holding or permanently discontinuing the immunotherapy based on severity 1, 2, 4